October 17, 2019
Sensorion has the last patient’s last visit in SENS-111 phase 2 clinical trial
Out of 105 patients were enrolled and treated in Sensorion’s SENS-111 Phase 2 trial, the last patient’s last visit of…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sensorion
August 7, 2019
Sensorion Announces Appointment of John Furey, Former COO of Spark Therapeutics, as Independent Board Member
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel…
June 28, 2019
Sensorion gets EMA’s Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in two indications
Sensorion gets EMA’s agreemtn, which paves the way for the submission of a marketing authorization application in Europe
March 27, 2019
Sensorion Reports Its 2018 Annual Results; 75% of Patients Enrolled in the Sens-111 Clinical Trial
SENS-111 phase 2 AUV trial: major progress with 75% of patients enrolled in the clinical trial assessing the efficacy of…
April 13, 2017
Sensorion welcomes new CEO
Sensorion, a biotech company specializing in the treatment of inner ear diseases, has appointed Nawal Ouzren as the Company’s new CEO.
January 26, 2017
Sensorion receives €950,000 from Bpifrance and the Occitania Region
Bpifrance and the Occitania region of Southern France have selected to support Sensorion, a biotechnology company specializing in the treatment…
October 14, 2016
Sensorion reports €4.3M loss for first half of 2016
Net loss amounts to €4.3M at June 30, 2016, compared with a net loss of €1.5M at June 30, 2015.